Article

Long-acting depot formulations of naltrexone for heroin dependence: a review.

Laboratory of Clinical Psychopharmacology of Addictions, Valdman Institute of Pharmacology, St Petersburg State Pavlov Medical University, St Petersburg, Russia.
Current opinion in psychiatry (Impact Factor: 3.55). 03/2010; 23(3):210-4. DOI: 10.1097/YCO.0b013e3283386578
Source: PubMed

ABSTRACT The major problem with the oral formulation of naltrexone for heroin dependence is poor compliance (adherence). Long-acting sustained release formulations of naltrexone (implantable and injectable) might help to improve compliance and, thus, increase the efficacy of abstinence-oriented treatment of heroin dependence with naltrexone.
There have been several implantable and injectable formulations of naltrexone developed within the last decade. It was demonstrated that some of them are effective and relatively well tolerated medications for relapse prevention in heroin addicts. However, advantages and disadvantages of these new medications have never been systematically analyzed.
Long-acting sustained release formulations of naltrexone are well tolerated and more effective for relapse prevention in heroin addicts than the oral ones.

1 Follower
 · 
185 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gambling disorder (GD) is becoming increasingly prevalent both among adults and adolescents. Unfortunately, this disorder is largely underestimated, while it can still lead to serious social and personal consequences, including criminal behavior or suicide attempts. In the past, the only means of treating gambling were psychobehavioral therapies. Nowadays, this disorder could also respond to many drugs from different classes such as opioid antagonists, serotonin selective reuptake inhibitors, mood stabilizers, atypical antipsychotics or glutamatergic agents. This review presents current pharmacological strategies and the results of clinical trials evaluating the efficacy of pharmacotherapy for GD. It also discusses the importance of distinguishing different pathological gambler subtypes such as impulsive, obsessive-compulsive and addictive subtypes as this may have serious pharmacological implications.
    Pharmacological reports: PR 10/2014; 66(5):811–820. DOI:10.1016/j.pharep.2014.05.003 · 2.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Method Visual analogue scale ratings of the likelihood of accepting a naltrexone injection were obtained from 61 male prisoners (mean age = 37.8 years (SD = 6.8 years) with a history of opiate misuse, who were in the final month of their sentence in one of two prisons on Merseyside in the north-west of England. Additional measures concerning past drug use, treatment, previous criminal convictions, demographic variables were taken, and established psychometric measures of preparedness for drug misuse treatment (Leeds Dependence Questionnaire, SOCRATES, and self-efficacy) were administered. Results Maximum likelihood ratings of accepting injectable naltrexone were recorded by 34 (55.7%) participants, with only 6 participants (9.8%) recording likelihood ratings of zero. The prevalence of maximum likelihood ratings reduced the variability of scores on this scale, consequently making it difficult to perform correlation and regression analyses with other variables. However, the likelihood of accepting injectable naltrexone was negatively correlated with maximum methadone dosage levels during the current sentence, whilst the negative correlation with the SOCRATES ‘Ambivalence’ scale approached significance. Participants currently incarcerated for acquisitive crimes recorded significantly higher naltrexone likelihood ratings than those incarcerated for drug related offences or violent crimes. Conclusions The potential uptake rate for naltrexone by injection amongst prisoners with a history of opiate misuse, indicated by these results, is sufficient to suggest that further investigation be made regarding the utility of this treatment in curbing the excessive mortality rate amongst this population in the immediate post-discharge period.
    The British Psychological Society Psychobiology Section Annual Scientific Meeting held 3rd-5th September 2014.Poster., Windermere; 09/2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: People with opioid dependence and HIV are concentrated within criminal justice settings (CJS). Upon release, however, drug relapse is common and contributes to poor HIV treatment outcomes, increased HIV transmission risk, reincarceration and mortality. Extended-release naltrexone (XR-NTX) is an evidence-based treatment for opioid dependence, yet is not routinely available for CJS populations.
    Contemporary Clinical Trials 09/2014; DOI:10.1016/j.cct.2014.09.002 · 1.99 Impact Factor

Full-text (2 Sources)

Download
79 Downloads
Available from
May 22, 2014